Neurocrine Biosciences Presents INGREZZA Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's disease Through Week 50 at Huntington Study Group 2023
SAN DIEGO - Neurocrine Biosciences, Inc. today announced interim results from the ongoing open-label KINECT-HD2 study about INGREZZA capsules when used for the long-term treatment of adults with...
Source: marketscreener.com